Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia
A Meta-Analysis
Datos Bibliográficos
| ID | 15529005 |
|---|---|
| Autores | Saeed Ahmed (0000-0001-9680-4553, Nassau University Medical Center), Sanya Virani (0000-0003-3330-2374, Maimonides Medical Center), Vijaya Padma Kotapati (0000-0002-1135-2090, Manhattan Psychiatric Center, autor de correspondencia), Ramya Bachu (Zucker Hillside Hospital), Mahwish Adnan (0000-0002-4608-1729, McMaster University), Ali Khan (0000-0002-3577-3770, The University of Texas Rio Grande Valley), Ali M Khan, Aarij Zubair (0000-0003-3629-6184, St. John's University), Gulshan Begum (Manhattan Psychiatric Center), Jeevan Kumar (Bolan Medical College), Mustafa Qureshi (Texas Tech University), Rizwan Ahmed (0000-0001-6877-2662, Liaquat National Hospital) |
| Año | 2018 |
| Volumen | 9 |
| Páginas | 428-428 |
| Fecha de publicación | 2018-09-19 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | Frontiers in Psychiatry (JOURNAL) |
| Identificadores de la revista | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Editorial | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2018.00428 |
| PMID | 30283363 |
| OpenAlex | W2889207821 |
| Idioma | EN |
| Citas recibidas | 3 |
| Referencias citadas | 61 |
Objective: Smoking represents a major public health problem among patients with schizophrenia. To this end, some studies have investigated the efficacy of varenicline for facilitating smoking cessation in schizophrenia patients. The present review seeks to synthesize the results of these studies as well as document the reported side effects of using this medication. Methods: An electronic search was performed using five major databases: PubMed, Scopus, EMBASE, Web of Science, and Cochrane Library. Included in the current analysis were randomized clinical trials (RCTs) that have investigated the effect of varenicline in promoting smoking cessation in patients with schizophrenia. Risk of bias among included RCTs was assessed using the Cochrane Collaboration's quality assessment tool. Results: Among the 828 screened articles, only four RCTs, which involved 239 participants, were eligible for meta-analysis. In patients with schizophrenia, varenicline treatment when compared to placebo significantly reduced the number of cigarettes consumed per day [SMD (95% CI) = 0.89(0.57-1.22)] and expired carbon monoxide levels [SMD (95% CI) = 0.50 (0.06-0.94)] respectively. Conclusion: Despite a limited number of studies included in the meta-analysis, our results suggest that varenicline is an effective and safe drug to assist smoking cessation in patients with schizophrenia. Future large-scale well-designed RCTs are required to validate these findings
Alternative medicine · Cochrane Library · Meta-analysis · Placebo · Psychiatry · Randomized controlled trial · Schizophrenia (object-oriented programming · Smoking cessation · Varenicline · Child and Adolescent Psychosocial and Emotional Development · Medicine · Obesity, Physical Activity, Diet · Smoking Behavior and Cessation · Internal Medicine
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs.
A Systematic Review of Mortality in Schizophrenia
A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Conducting Meta-Analyses in R with the metafor Package
| Obras citantes distintas | 3 |
|---|---|
| Citas por año | 0,6 |
| Intervalo de citas | 2021 - 2023 (3) |
| Velocidad de citación | historical |
| Altamente citado | No |
| Tipos de cita | Neutras: 3 |